Should I buy or sell AnaptysBio stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ANAB shares. View ANAB analyst ratings or view top-rated stocks .

What is AnaptysBio's stock price target for 2024?

10 equities research analysts have issued 1 year price targets for AnaptysBio's stock. Their ANAB share price targets range from $21.00 to $80.00. On average, they expect the company's stock price to reach $46.22 in the next year. This suggests a possible upside of 133.1% from the stock's current price. View analysts price targets for ANAB or view top-rated stocks among Wall Street analysts .

How have ANAB shares performed in 2024?

AnaptysBio's stock was trading at $21.42 at the beginning of the year. Since then, ANAB shares have decreased by 7.4% and is now trading at $19.83. View the best growth stocks for 2024 here .

When is AnaptysBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ANAB earnings forecast .

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings results on Monday, March, 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.74) by $0.15. The biotechnology company earned $9.01 million during the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative trailing twelve-month return on equity of 119.42%.

What ETF holds AnaptysBio's stock?

Virtus LifeSci Biotech Clinical Trials ETF holds 4,551 shares of ANAB stock, representing 0.91% of its portfolio.

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE) , ImmunoGen (IMGN) , NVIDIA (NVDA) , CRISPR Therapeutics (CRSP) , Amarin (AMRN) , Editas Medicine (EDIT) , Illumina (ILMN) , Clovis Oncology (CLVS) , Twilio (TWLO) and AbbVie (ABBV) .

When did AnaptysBio IPO?

AnaptysBio (ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are AnaptysBio's major shareholders?

AnaptysBio's stock is owned by a number of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Daniel Faga, Dennis Mulroy, Ecor1 Capital, Llc, Eric J Loumeau, Eric J Loumeau , Hamza Suria and Paul F Lizzul. View institutional ownership trends .

How do I buy shares of AnaptysBio?

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ANAB

AnaptysBio (ANAB) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free ANAB Stock Alerts

$19.83

-1.64 (-7.64%)

(As of 04/18/2024 ET)

Compare

Today's Range: $19.79
▼
$21.78
50-Day Range: $20.67
▼
$26.47
52-Week Range: $13.36
▼
$27.50

Volume: 363,855 shs
Average Volume: 313,406 shs
Market Capitalization: $530.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $46.22

Get AnaptysBio alerts:

AnaptysBio MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 133.1% Upside
$46.22 Price Target
Short Interest: Bearish
18.16% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.72
Based on 16 Articles This Week
Insider Trading: Selling Shares
$3.59 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($6.25) to ($5.86) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.51 out of 5 stars

Medical Sector

459th out of 919 stocks

Pharmaceutical Preparations Industry

203rd out of 410 stocks

4.4

Analyst's Opinion

Consensus Rating
AnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
AnaptysBio has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
18.16% of the float of AnaptysBio has been sold short.
Short Interest Ratio / Days to Cover
AnaptysBio has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.
Change versus previous month
Short interest in AnaptysBio has recently increased by 3.86%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
AnaptysBio does not currently pay a dividend.
Dividend Growth
AnaptysBio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ANAB.

2.6

News and Social Media Coverage

News Sentiment
AnaptysBio has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 16 news articles for AnaptysBio this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for ANAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,586,199.00 in company stock.
Percentage Held by Insiders
35.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AnaptysBio are expected to grow in the coming year, from ($6.25) to ($5.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AnaptysBio is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AnaptysBio is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AnaptysBio has a P/B Ratio of 5.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About AnaptysBio Stock (NASDAQ:ANAB)

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

ANAB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ANAB Stock News Headlines

March 27, 2024 | insidertrades.com

Daniel Faga Sells 3,000 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock

April 18, 2024 | americanbankingnews.com

Leerink Partnrs Reiterates Outperform Rating for AnaptysBio (NASDAQ:ANAB)

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 17, 2024 | msn.com

Leerink Partners Initiates Coverage of AnaptysBio (ANAB) with Outperform Recommendation

April 17, 2024 | americanbankingnews.com

AnaptysBio (NASDAQ:ANAB) Receives New Coverage from Analysts at SVB Leerink

April 15, 2024 | investorplace.com

BTIG Research Predicts Over 118% Rally for These 3 Stocks

April 14, 2024 | americanbankingnews.com

AnaptysBio (NASDAQ:ANAB) Shares Down 8.2%

April 13, 2024 | americanbankingnews.com

AnaptysBio (NASDAQ:ANAB) Shares Gap Up to $22.17

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 12, 2024 | fool.com

Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

April 12, 2024 | americanbankingnews.com

AnaptysBio (NASDAQ:ANAB) Now Covered by Analysts at Wells Fargo & Company

April 1, 2024 | markets.businessinsider.com

Unveiling 4 Analyst Insights On AnaptysBio

March 18, 2024 | finance.yahoo.com

Industry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts

March 12, 2024 | markets.businessinsider.com

Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers

March 12, 2024 | seekingalpha.com

Wedbush raises AnaptysBio to outperform, cites upcoming data

March 12, 2024 | markets.businessinsider.com

J.P. Morgan Reaffirms Their Hold Rating on AnaptysBio (ANAB)

March 12, 2024 | finanznachrichten.de

AnaptysBio, Inc.: Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 11, 2024 | globenewswire.com

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 11, 2024 | finance.yahoo.com

ANAB Mar 2024 20.000 call

February 29, 2024 | globenewswire.com

Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting

February 27, 2024 | msn.com

BTIG Initiates Coverage of AnaptysBio (ANAB) with Buy Recommendation

February 24, 2024 | msn.com

AnaptysBio (ANAB) Price Target Increased by 40.21% to 38.61

February 22, 2024 | benzinga.com

AnaptysBio Stock (NASDAQ:ANAB) Insider Trades

February 22, 2024 | msn.com

Stifel Initiates Coverage of AnaptysBio (ANAB) with Buy Recommendation

February 21, 2024 | msn.com

Stifel starts AnaptysBio at buy, cites upcoming catalysts

February 21, 2024 | msn.com

Palo Alto Networks, Home Depot downgraded: Wall Street's top analyst calls

February 21, 2024 | investing.com

Anaptysbio a key player in next wave of immune cell modulatory therapies - Stifel

See More Headlines

Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ANAB
CUSIP: N/A
CIK: 1370053
Web: www.anaptysbio.com
Phone: (858) 362-6295
Fax: N/A
Employees: 117
Year Founded: 2005

Price Target and Rating

Average Stock Price Target: $46.22
High Stock Price Target: $80.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +129.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-163,620,000.00
Net Margins: -953.66%
Pretax Margin: -953.68%
Return on Equity: -119.42%
Return on Assets: -32.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.87
Quick Ratio: 10.87

Sales & Book Value

Annual Sales: $17.16 million
Price / Sales: 31.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.32 per share
Price / Book: 6.08

Miscellaneous

Outstanding Shares: 26,760,000
Free Float: 17,262,000
Market Cap: $539.75 million
Optionable: Optionable
Beta: -0.30

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Daniel R. Faga (Age 44)
President, CEO & Director
Comp: $867.12k
Mr. Eric J. Loumeau (Age 61)
Chief Legal Officer
Comp: $685.59k
Dr. James Newman Topper M.D. (Age 62)
Ph.D., Advisor
Comp: $86.5k
Dr. Paul F. Lizzul FAAD (Age 49)
M.B.A., M.D., M.P.H., Ph.D., Chief Medical Officer
Comp: $656.36k
Mr. Dennis M. Mulroy (Age 69)
Chief Financial Officer
Comp: $448.81k
Ms. Beth Mueller
Senior Vice President of Human Resources
Dr. Martin Dahl Ph.D.
Senior Vice President of Research
Mr. Benjamin Stone
Chief Business Officer
Mr. Douglas A. Rich M.B.A. (Age 55)
Senior Vice President of CMC
Ms. Monique Da Silva
Senior Vice President of Corporate Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ANAB Stock Analysis - Frequently Asked Questions

Should I buy or sell AnaptysBio stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ANAB shares.
View ANAB analyst ratings or view top-rated stocks.
What is AnaptysBio's stock price target for 2024?: 10 equities research analysts have issued 1 year price targets for AnaptysBio's stock. Their ANAB share price targets range from $21.00 to $80.00. On average, they expect the company's stock price to reach $46.22 in the next year. This suggests a possible upside of 133.1% from the stock's current price.
View analysts price targets for ANAB or view top-rated stocks among Wall Street analysts.
How have ANAB shares performed in 2024?: AnaptysBio's stock was trading at $21.42 at the beginning of the year. Since then, ANAB shares have decreased by 7.4% and is now trading at $19.83.
View the best growth stocks for 2024 here.
When is AnaptysBio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ANAB earnings forecast.
How were AnaptysBio's earnings last quarter?: AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings results on Monday, March, 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.74) by $0.15. The biotechnology company earned $9.01 million during the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative trailing twelve-month return on equity of 119.42%.
What ETF holds AnaptysBio's stock?: Virtus LifeSci Biotech Clinical Trials ETF holds 4,551 shares of ANAB stock, representing 0.91% of its portfolio.

What other stocks do shareholders of AnaptysBio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).
When did AnaptysBio IPO?: AnaptysBio (ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are AnaptysBio's major shareholders?: AnaptysBio's stock is owned by a number of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Daniel Faga, Dennis Mulroy, Ecor1 Capital, Llc, Eric J Loumeau, Eric J Loumeau, Hamza Suria and Paul F Lizzul.
View institutional ownership trends.
How do I buy shares of AnaptysBio?: Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANAB) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AnaptysBio (ANAB) Stock Price, News & Analysis

AnaptysBio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AnaptysBio Stock (NASDAQ:ANAB)

ANAB Stock Price History

ANAB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ANAB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™